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Abstract
Background: The development of primary hyperparathyroidism (PHPT) after
radioactive iodine (RAI) treatment for thyroid disease is poorly characterized.
The current study is the largest reported cohort and assesses the disease characteristics of patients treated for PHPT with a history of RAI exposure.
Methods: A retrospective analysis comparing patients, with and without a history of RAI treatment, who underwent surgery for PHPT.
Results: Twenty-eight of the 469 patients had a history of RAI treatment, all
for Graves' disease. Patients with a history of RAI exposure had similar disease
characteristics compared to control; however, patients with a history of RAI
treatment had a higher rate of recurrence (7.4% vs 1.2%, p = 0.012).
Conclusion: PHPT in patients with a history of RAI treatment can be
approached in the same manner as RAI naive PHPT patients; however, the
risk of recurrence of PHPT in RAI exposed patients may be higher.
KEYWORDS

Graves' disease, hypercalcemia, hyperparathyroidism, parathyroid surgery, radioactive
iodine

1 | INTRODUCTION
The development of primary hyperparathyroidism
(PHPT) after radioactive iodine (RAI) treatment for thyroid disease has been described, but not well studied. The
literature on this topic consists mostly of case reports and
case series.1–16 The overwhelming majority of patients in
these reports received RAI for Graves' disease,2,3,5,8,9,16,17
but other indications include thyroid malignancy2,6,7,10,14,18 and benign goiters.1,3,4,11,14 In terms of
etiology, the existence of RAI-induced PHPT as a truly
unique entity has been debated; some studies report no
increased risk of PHPT after exposure to RAI,6,10,13,19
while others suggest an association with PHPT development.2–4,7,14,15,17,20 Additionally, it remains unclear if
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PHPT occurring after RAI exposure presents with a distinct clinical phenotype. In the reports on these
patients, there is a female predominance and a higher
predilection in the middle aged and elderly. While most
patients reportedly present 10–20 years after administration of RAI,2,3,5,6,11,14,17,18,21 the time lapse is highly
variable.
Previous studies describing PHPT in patients with a
history of RAI consisted of small sample sizes, having
fewer than 11 patients in their reports. As a result, there
are fewer than 100 cases documented in the medical literature. This current study describes the largest cohort
to date. The aim of this study was to better characterize
this disease entity by examining the clinicopathologic
characteristics of patients presenting for surgical
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management of PHPT with and without a history of
RAI treatment.

not meet these standards, the remainder of the parathyroid glands was sought and assessed.

2 | MATERIALS AND METHODS

2.2 | Determination of
postoperative cure

This was a single institution retrospective cohort study of
497 patients undergoing first time parathyroidectomy for
PHPT from July 2015 to February 2020. The study was
approved by the Henry Ford Health System's Institutional Review Board, IRB #14143. This study conforms to
the ethical principles for medical research involving
human subjects as described in the Declaration of
Helsinki. The diagnosis of PHPT was established by an
elevated or inappropriately suppressed serum parathyroid
hormone (PTH) in the setting of hypercalcemia. No
patients with normocalcemic hyperparathyroidism were
included in this study, as the senior author does not routinely operate on patients with this diagnosis. Patients
with a history of parathyroid surgery were excluded from
this study.
Information collected via chart review included
patient demographics, symptoms, history of RAI treatment, prior neck surgeries, results of imaging studies,
preoperative, intraoperative and postoperative laboratory
values, operative time, and pathology reports. Two
groups were created from the database: patients with
PHPT with a history of RAI treatment and patients
with PHPT without a history RAI treatment. The two
groups were compared. A subgroup analysis was also
performed.

2.1 | Surgical technique
Surgical intervention entailed either a minimally invasive
(focused) parathyroidectomy or bilateral neck exploration. The type of surgery was dictated by multiple patient
and disease factors, including results of imaging studies
and intraoperative findings. A sestamibi scan and a
surgeon-performed ultrasound (US) were routinely
obtained. In the overall cohort, a 4D CT scan was
obtained in select patients if both the former imaging
modalities were nonlocalizing. In all patients previously
treated with RAI, a 4D CT was obtained if the US and
sestamibi were nonlocalizing.
In all minimally invasive cases, intraoperative PTH
(ioPTH) levels were used to determine cure. Early in the
experience, the ioPTH criteria were a drop of ≥50% from
baseline ioPTH level by 10 min and into the normal
range. The more recent cases were performed using a
stricter protocol, which included a third criterion of the
ioPTH dropping below 40 pg/mL. If the ioPTH levels did

Cure was defined by becoming eucalcemic and
maintaining calcium (ionized, serum, and corrected
serum calcium) levels in the normal range for ≥6 months
from the time of surgery. Persistence was defined by continued hypercalcemia postoperatively that did not normalize. Recurrent disease was characterized by a period
of eucalcemia that lasted at least 6 months following surgery, followed by a return of the hypercalcemia.

2.3 | Statistical analysis
The continuous variables in this data set were not normally distributed. Medians and their interquartile range
(IQR; 25th to 75th percentile) were used as a result. Nominal variables were described with percentiles. The two
groups, those with PHPT with a history of RAI exposure
and those with PHPT who were not exposed to RAI, were
compared with a two-sample Wilcoxon test for continuous variables or a chi-square test for nominal variables.
The same statistical methodology was employed to compare those with multiglandular disease to those without
multiglandular disease within the RAI exposed group. All
analyses were done using SAS version 9.4 (SAS Institute
Inc, Cary, NC, USA). A p-value less than 0.05 was considered evidence of significance. A power analysis could not
be conducted as the incidence is not well described in the
literature with the literature only consisting of case
reports and case series. The study was conducted with a
sample size greater than previous studies.

3 | RESULTS
Of the 497 patients in the PHPT cohort, 469 patients met
criteria to be included in the study; 441 patients were in
the control group and 28 patients were in the RAI exposure group (Table 1). At least 6 months of follow-up data
were available for 27/28 RAI exposed patients and
426 patients in the control group. In the control group,
76.9% (339) were female and 82.1% (23) were female in
the RAI group. The incidence of PHPT with RAI exposure in the total study cohort was 5.97% (28/469). The
median ages were 61.0 years (IQR 52.0–68.0) and
65.0 years (IQR 52.0–71.5) for the control group and RAI
group, respectively (p = 0.142). There was no statistical
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TABLE 1

Comparison of preoperative and intraoperative metrics control versus RAI
Control

Variable

N

Age (years)
2

BMI (kg/m )

RAI
Median

IQR

N

Median

IQR

p

441

61.0

52.0–68.0

28

65.0

52.0–71.5

0.142

440

30.3

25.9–34.7

28

30.8

26.0–33.2

0.787

Preoperative
Intact PTH (pg/mL)

440

114.0

83.0–155.0

28

118.0

92.5–169.5

0.666

Vitamin D (ng/mL)

436

24.0

19.0–31.0

28

25.5

18.5–35.0

0.608

Ionized calcium (mmol/L)

436

Corrected calcium (mg/dL)

436

Creatinine (mg/dL)

438

1.44

1.35–1.54

10.9

10.5–11.3

0.82

28
28

0.68–1.04

28

28

1.38
11.0
0.84

1.33–1.49
10.6–11.4

0.103
0.573

0.70–1.05

0.559

118.9–210.7

0.801

Intraoperative
Baseline ioPTH (pg/mL)

439

160.5

114.0–228.6

170.7

Last ioPTH (pg/mL)

440

22.6

15.9–33.4

28

25.1

17.7–36.9

0.523

Operative time (min)

441

69.0

58.2–91.0

28

73.7

57.2–89.0

0.829

Maximum mass adenoma (mg)

420

700.0

350.0–1402.0

27

723.0

300.0–1600.0

0.872

Abbreviations: BMI, body mass index; ioPTH, intraoperative parathyroid hormone; IQR, interquartile range; N, number of patients in the respective group;
PTH, parathyroid hormone; RAI, radioactive iodine.

TABLE 2
versus RAI

Comparison of cure rate and disease subtype control

Variable

Control
% (R/N)

RAI
% (R/N)

p*

Female

76.9 (339/441)

82.1 (23/28)

0.519

Kidney stones

26.3 (116/441)

17.9 (5/28)

0.322

Multiglandular
disease

16.6 (73/439)

14.3 (4/28)

0.746

Disease type

0.129

Single gland

83.4 (366/439)

85.7 (24/28)

Double gland

7.5 (33/439)

14.3 (4/28)

4-gland hyperplasia

9.1 (40/439)

0 (0/28)
0.032

Recurrence/
persistence
Cured

98.4 (419/426)

100 (27/27)

0.508

Persistence

1.6 (7/426)

0 (0/27)

0.508

Recurrence

1.2 (5/419)

7.4 (2/27)

0.012

Abbreviations: %, percentage; N, total number of patients in the respective
group; R, number of patients with the characteristics as dictated by the
respective variable; RAI, radioactive iodine.
*Significant p values are bolded and italicized.

difference with regard to the history of nephrolithiasis
between the two groups (Table 2). The median time from
the RAI treatment until diagnosis with PHPT was
20 years (IQR 18–30). The median preoperative intact
PTH and corrected calcium levels were similar between

the groups (Table 1). There were no statistically significant differences in the vitamin D, ionized calcium, and
creatinine levels between the two groups (Table 1). With
regard to imaging, 22/28 patients had a localizing,
surgeon-performed US, and/or sestamibi scan. The
remaining six patients additionally underwent a 4D CT
scan. Of these, three provided localizing information.
Of the 28 patients, 16 were managed with the initial
ioPTH regimen and 12 with the modified protocol. The
median baseline ioPTH levels were 160.5 pg/mL (IQR
114.0–228.6) and 170.7 pg/mL (IQR 118.9–210.7) for the
control and RAI groups, respectively (p = 0.801), with a
median reduction in ioPTH levels at 10 min postexcision
of the pathologic gland(s) to 22.6 pg/mL (IQR 15.9–33.4)
and 25.1 pg/mL (17.7–36.9), respectively (p = 0.523).
There were no statistical differences in operative time or
adenoma mass (or largest pathological gland if multiple
were present) between the two groups (Table 1). There
was also no statistical difference in rate for multiglandular disease between the two groups (p = 0.129). Of
note, the RAI group did not have any patients with
4-gland hyperplasia (Table 2). The cure rate was similar
in the two groups, 98.4% (419/426) in the control group
compared to 100% (27/27) in the RAI group (p = 0.508).
Perhaps, the most notable difference between the
groups was in recurrence rate. Only 1.2% (5/419) of
the control group was found in follow-up to have recurrent disease, in contrast with the RAI group in which the
recurrence rate was 7.4% (2/27) (p = 0.012). In both of
the patients with recurrence, at the time of surgery a
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TABLE 3

Subgroup analysis of RAI group—single gland versus multiglandular disease
RAI single gland

Variable

N

Age (years)
2

BMI (kg/m )

RAI multiglandular

Median

IQR

N

Median

IQR

p*

24

66.5

55.0–72.0

4

58.0

54.4–62.0

0.177

24

30.6

26.0–32.5

4

32.4

28.2–34.3

0.512

Preoperative
Intact PTH (pg/mL)

24

118.0

92.5–165.0

4

133.5

87.5–190.0

0.844

Vitamin D (ng/mL)

24

25.5

18.5–32.5

4

29.0

20.0–38.5

0.532

Ionized calcium (mmol/L)

24

Corrected calcium (mg/dL)

24

Creatinine (mg/dL)

24

1.38

1.33–1.49

11.0

10.6–11.5

0.84

4
4

0.66–1.05

4

132.3–239.9

4

1.36
11.0
0.91

1.28–1.50
10.5–11.1

0.599
0.554

0.79–1.46

0.341

94.6–193.6

0.431

Intraoperative
Baseline ioPTH (pg/mL)

24

178.0

135.1

Last ioPTH (pg/mL)

24

29.1

18.2–38.0

4

18.4

8.8–21.8

0.088

Operative time (min)

24

70.5

56.3–79.6

4

127.8

110.3–179.6

0.004

Maximum mass adenoma (mg)

23

800.0

500.0–1600.0

4

355.0

200.0–1250.0

0.269

Abbreviations: BMI, body mass index; ioPTH, intraoperative parathyroid hormone; IQR, interquartile range; N, number of patients in the respective group;
PTH, parathyroid hormone; RAI, radioactive iodine.
*Significant p values are bolded and italicized.

Variable

RAI single gland
% (R/N)

RAI multiglandular
% (R/N)

p

Female

79.2 (19/24)

100.0 (4/4)

1.000

Kidney stones

20.9 (5/24)

0 (0/4)

1.000

Recurrence/persistence
Cured
Recurrence

T A B L E 4 Comparison of cure rate
for RAI subgroup analysis—single
gland versus multiglandular disease

1.000
91.3 (21/23)
8.7 (2/23)

100 (4/4)

1.000

0 (0/4)

1.000

Abbreviations: %, percentage; N, total number of patients in the respective group; R, number of patients
with the characteristics as dictated by the respective variable; RAI, radioactive iodine.

single, adenomatous gland was removed and ioPTH
levels were consistent with cure. Both were operated on
during the period when the stricter ioPTH criteria were
being employed. However, after experiencing a period of
eucalcemia of at least 6 months, both demonstrated
recurrent hypercalcemia.
A subgroup analysis was performed for the RAI group
comparing patients with single gland disease to those
with multiglandular disease. There were no statistically
significant differences between groups in the preoperative, intraoperative, or postoperative metrics except for
operative time (Tables 3 and 4). As mentioned, there
were no cases of 4-gland hyperplasia in the RAI group,
but there were two cases of double adenomas, which
required additional time for exploration. The median
operative times were 70.5 min (IQR 56.3–79.6) and
127.8 min (110.3–179.6) for the single gland group and

multiglandular group, respectively (p = 0.004). There was
no statistical difference in cure rates between these two
groups (Table 4).

4 | DISCUSSION
The available literature on the development of PHPT
after the RAI treatment for thyroid disease consists
mostly of case reports and small case series.1–16 In these
publications, a majority of the patients were treated with
RAI for the treatment of Graves' disease. Additional indications include adjuvant therapy for thyroid cancer and
benign goiters. Little is known about the characteristics
of the PHPT in these patients. Some reports suggest that
there is no increased risk in developing PHPT after RAI
treatment,6,10,13,19 while others suggest that there is an
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association between RAI exposure and the development
of PHPT.2–4,7,14,15,17,20
The incidence and prevalence of this entity is not
known, but in this cohort nearly 6% of the patients
undergoing surgery for PHPT had a history of prior RAI
treatment. While the percentage of the general population that has been treated with RAI is not known, the
incidence in this cohort seems comparatively high,
suggesting a possible causative relationship. However, it
remains unclear if this causative association is real. Is
RAI exposure just a confounder? External beam radiation
to the thyroid gland has been shown to increase the risk
of developing PHPT and is a more well-established
risk factor than RAI.20,22–24 Studies with murine models
have shown an increased incidence or more rapid development of PHPT after exposure to RAI when compared
to control rodents.3,25,26 Unfortunately, there are no large
prospective studies examining this question in humans.
Although there is some evidence to support the entity of
RAI-induced PHPT, the mechanism of how RAI
increases the risk of developing of PHPT is unknown and
speculative at best.3 The question of what dose and duration of RAI exposure puts patients at a higher risk for
developing PHPT also remains unknown.19 To better
characterize the possible relationship and mechanism of
RAI-induced PHPT, larger prospective studies would be
needed. RAI is known to have a number of potential side
effects and it is possible that the risk of developing PHPT
should be added as a potential consideration.27
As the literature on this topic is limited, the clinical
presentation of these patients remains unclear. The
latency period from the time of RAI treatment to
the development of PHPT is not well studied.2,3,5,6,11,14,17,18,21 Bondeson et al. quote a latency
period range of 3–27 years in their 10 patient case series.2
Wei et al. report a latency range of 12–14 years in their
cohort of 11 patients.17 One study, which combined an
institutional cohort of 11 patients with 36 patients
described in the literature, describes a range of 3–30 years
with a mean of 35 ± 19.5 years.3 This group also reported
that with increasing age at the time of RAI treatment, the
latency period to developing PHPT decreased. In our
cohort, the average latency period was 20 years.
The current study, which includes the largest cohort
studied to date, found that with regard to most clinical
measures, the RAI exposed patients were similar to nonRAI patients. There were no statistically significant
differences in gender, incidence of nephrolithiasis, preoperative calcium, vitamin D, creatinine or PTH levels, or
gland weights. Wei et al.'s study, the only other retrospective cohort study examining this topic (which included
11 patients exposed to RAI), described similar findings.
As RAI ablates the thyroid and consequently can alter
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the normal anatomy, these cases could potentially be
more challenging and time intensive. However, we found
no difference in average operative time between the
cohorts.
Several relevant findings from this study have not
previously been reported. Given that RAI may induce
mutations in the parathyroid glands of the RAI exposed
cohort, a higher rate of multiglandular disease might be
expected in these patients. However, in our cohort, the
overall rate of multiglandular disease was similar
between the groups. Interestingly, none of the RAI
exposed patients were found to have 4-gland hyperplasia.
These results suggest that patients with PHPT who have
had prior RAI exposure have a similar disease phenotype
as those without prior RAI exposure. Importantly, we
found no statistically significant difference in cure rates
between the RAI and control group. This includes a large
number of patients who were managed with minimally
invasive parathyroidectomy (and ioPTH levels).
While the cure rate was similar between the two
groups, the recurrence rate was statistically greater in
patients who had been exposed to RAI. Historically,
recurrence after a curative parathyroidectomy (in which
a single adenoma was excised) was thought to be quite
uncommon. However, more recent data suggest that
recurrence is a more common issue than traditionally
thought.28,29 The higher recurrence rate in our cohort
calls for some speculation regarding possible etiology.
The two RAI exposed patients who recurred had a single
gland removed during surgery and met the stricter ioPTH
protocol. Consequently, these patients appear to have
experienced true sequential adenomas. While this can
occur in any patient with PHPT, it is possible that RAI
exposure does in fact increase the risk. It is important to
recognize that while statistically significant, this result
was found in a very limited sample size. Consequently,
the strength of this finding should be considered carefully
by surgeons. In addition, a potential confounding factor
to this finding is that due to the history of Graves' disease
and RAI therapy, a greater percentage of these patients
compared to the control group might have been under
the continued care of an endocrinologist, leading to a
higher rate of diagnosis. Nonetheless, greater vigilance
when counseling and monitoring these patients after surgery is likely prudent.
One limitation of the current study was that some
patients did not remember when they received RAI treatment and it was not in the medical record; as a result, the
ability to precisely determine the median latency time
was limited. There were also limitations due to the retrospective nature of this study. A larger prospective cohort
study would provide stronger evidence. Although this is
the largest retrospective cohort study, the true incidence
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of RAI-induced PHPT is not known and therefore a
power analysis could not be accurately calculated.

5 | C ON C L U S I ON
In this study, patients with PHPT with a history of treatment with RAI were found to present with a similar clinical presentation to RAI naïve PHPT patients.
Importantly, the frequency of multiglandular pathology
was similar between the two groups. Consequently, RAI
exposed patients can be approached in the same surgical
manner typically employed by surgeons. While surgeons
and patients in this scenario can expect a similar cure
rate with surgery, they should be aware that the risk of
recurrence may be increased.
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